Patient Characteristics and Outcomes of Hospitalized Chronic Kidney Disease Patients with and without Type 2 Diabetes Mellitus: Observations from the German Claims Data-Based Cohort of the CaReMe-CKD Multinational Study

References

• Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. doi:10.1016/s0140-6736(20)30045-3
   PubMed Web of Science ®Google Scholar
• Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: the CaReMe CKD study. Lancet Region Health. 2022;20:100438. doi:10.1016/j.lanepe.2022.100438
   PubMedGoogle Scholar
• Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
   PubMed Web of Science ®Google Scholar
• Matsushita K, Kaptoge S, Hageman SH, et al. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Euro J Prevent Cardiol. 2022. doi:10.1093/eurjpc/zwac176
   Google Scholar
• Anders H-J, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–377. doi:10.1038/s41581-018-0001-y
   PubMed Web of Science ®Google Scholar
• Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121–132. doi:10.1053/j.ackd.2017.10.011
   PubMed Web of Science ®Google Scholar
• Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012. BMJ Open Diabetes Res Care. 2016;4(1):e000154. doi:10.1136/bmjdrc-2015-000154
   PubMed Web of Science ®Google Scholar
• Brück K, Stel VS, Gambaro G, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016;27(7):2135–2147. doi:10.1681/asn.2015050542
   PubMedGoogle Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–2883. doi:10.2337/dc14-1296
   PubMed Web of Science ®Google Scholar
• Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81. doi:10.1038/nrneph.2015.173
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayer WC, Nally JV. Diabetes control and the risks of ESRD and Mortality in Patients With CKD. Am J Kidney Dis. 2017;70(2):191–198. doi:10.1053/j.ajkd.2016.11.018
   PubMed Web of Science ®Google Scholar
• Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol Dial Transplant. 2017;32(1):97–110. doi:10.1093/ndt/gfw070
   PubMed Web of Science ®Google Scholar
• Wanner C, Schuchhardt J, Bauer C, et al. Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. J Nephrol. 2022;36(1):45–54. doi:10.1007/s40620-022-01340-x
   PubMedGoogle Scholar
• Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252. doi:10.1016/S0140-6736(16)32064-5
   PubMed Web of Science ®Google Scholar
• Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008;73(11):1310–1315. doi:10.1038/ki.2008.67
   PubMed Web of Science ®Google Scholar
• Zhang X, Fang Y, Zou Z, et al. Risk Factors for Progression of CKD with and without Diabetes. J Diabetes Res. 2022;2022:1–12. doi:10.1155/2022/9613062
   Google Scholar
• Go AS, Yang J, Tan TC, et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrol. 2018;19:1. doi:10.1186/s12882-018-0942-1
   PubMedGoogle Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/nejmoa2024816
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31. doi:10.1016/s2213-8587(20)30369-7
   PubMed Web of Science ®Google Scholar
• Darbà J, Marsà A. Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011–2017). J Med Econo. 2020;23(12):1623–1629. doi:10.1080/13696998.2020.1830782
   PubMed Web of Science ®Google Scholar
• Escobar C, Aranda U, Palacios B, et al. Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain. Nefrologia. 2021;41(6):670–688. doi:10.1016/j.nefroe.2022.01.008
   PubMedGoogle Scholar
• Hobson P, Kumwenda M, Shrikanth S, Nair H, Wong S. Risk and incidence of cognitive impairment in patients with chronic kidney disease and diabetes: the results from a longitudinal study in a community cohort of patients and an age and gender-matched control cohort in North Wales, UK. BMJ Open. 2022;12(3):e053008. doi:10.1136/bmjopen-2021-053008
   PubMedGoogle Scholar
• Palanca A, Castelblanco E, Perpiñán H, et al. Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes. Atherosclerosis. 2018;276:50–57. doi:10.1016/j.atherosclerosis.2018.07.018
   PubMedGoogle Scholar
• Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data: the AHRQ Elixhauser Comorbidity Index. Med Care. 2017;55(7):698–705. doi:10.1097/MLR.0000000000000735
   PubMed Web of Science ®Google Scholar
• Gasparini A. comorbidity: an R package for computing comorbidity scores. J Open Source Software. 2018;3(23):648. doi:10.21105/joss.00648
   Google Scholar
• Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi:10.1016/s0140-6736(07)61602-x
   PubMed Web of Science ®Google Scholar
• Morales J, Handelsman Y. Cardiovascular outcomes in patients with diabetes and kidney disease. J Am College Cardiol. 2023;82(2):161–170. doi:10.1016/j.jacc.2023.04.052
   PubMedGoogle Scholar
• Ronco C, Bellasi A, Di Lullo L. Cardiorenal Syndrome: an Overview. Adv Chronic Kidney Dis. 2018;25(5):382–390. doi:10.1053/j.ackd.2018.08.004
   PubMed Web of Science ®Google Scholar
• Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obesity Metab. 2020;22(S1):16–31. doi:10.1111/dom.13969
   PubMedGoogle Scholar
• Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1). doi:10.1186/s12933-018-0762-4
   PubMedGoogle Scholar
• Swamy S, Noor SM, Mathew RO. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023;12(22):6984. doi:10.3390/jcm12226984
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Anderson JE, Bakris GL, et al. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J diabet complicat. 2022;36(2):108101. doi:10.1016/j.jdiacomp.2021.108101
   Google Scholar
• Sasso FC, Pafundi PC, Simeon V, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021;20:1. doi:10.1186/s12933-021-01343-1
   PubMed Web of Science ®Google Scholar
• Piscitelli P, Viazzi F, Fioretto P, et al. Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-03551-w
   Google Scholar
• Johansen KL, Chertow GM, Gilbertson DT, et al. US Renal Data system 2021 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2022;79(4):A8–A12. doi:10.1053/j.ajkd.2022.02.001
   PubMed Web of Science ®Google Scholar
• Mariani L, Stengel B, Combe C, et al. The CKD Outcomes and Practice Patterns Study (CKDopps): rationale and Methods. Am J Kidney Dis. 2016;68(3):402–413. doi:10.1053/j.ajkd.2016.03.414
   PubMedGoogle Scholar
• Reichel H, Zee J, Tu C, et al. Chronic kidney disease progression and mortality risk profiles in Germany: results from the chronic kidney disease outcomes and practice patterns study. Nephrol Dial Transplant. 2020;35(5):803–810. doi:10.1093/ndt/gfz260
   PubMedGoogle Scholar
• Eckardt KU, Bärthlein B, Baid-Agrawal S, et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant. 2012;27(4):1454–1460. doi:10.1093/ndt/gfr456
   PubMedGoogle Scholar
• Titze S, Schmid M, Köttgen A, et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant. 2015;30(3):441–451. doi:10.1093/ndt/gfu294
   PubMedGoogle Scholar
• Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848. doi:10.1136/heartjnl-2016-310794
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021. doi:10.1093/eurheartj/ehab368
   Google Scholar
• Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–1591. doi:10.1016/j.ophtha.2021.04.027
   PubMed Web of Science ®Google Scholar
• Nationale Versorgungsleitlinie (NVL) Type 2-Diabetes (National guideline for type 2 diabetes mellitus). Available from: https://www.leitlinien.de/themen/diabetes/version-3. Accessed June 7, 2024.
   Google Scholar
• Federal Robert Koch Institute (RKI): diabetes surveillance in Germany. Available from: https://diabsurv.rki.de/Webs/Diabsurv/EN/diabetes-in-germany/adults/quality_type-2-diabetes_care/2-158_ophthalmological_examination.html. Accessed June 7, 2024.
   Google Scholar
• Kreft D, McGuinness MB, Doblhammer G, Finger RP. Diabetic retinopathy screening in incident diabetes mellitus type 2 in Germany between 2004 and 2013 - A prospective cohort study based on health claims data. PLoS One. 2018;13(4):e0195426. doi:10.1371/journal.pone.0195426
   PubMedGoogle Scholar
• Fazzini F, Lamina C, Raschenberger J, et al. Results from the German Chronic Kidney Disease (GCKD) study support association of relative telomere length with mortality in a large cohort of patients with moderate chronic kidney disease. Kidney Int. 2020;98(2):488–497. doi:10.1016/j.kint.2020.02.034
   PubMed Web of Science ®Google Scholar
• Pammer LM, Lamina C, Schultheiss UT, et al. Association of the metabolic syndrome with mortality and major adverse cardiac events: a large chronic kidney disease cohort. J Internal Med. 2021;290(6):1219–1232. doi:10.1111/joim.13355
   Google Scholar
• Mehring M, Donnachie E, Bonke FC, Werner C, Schneider A. Disease management programs for patients with type 2 diabetes mellitus in Germany: a longitudinal population-based descriptive study. Diabetol Metab Syndr. 2017;9(1). doi:10.1186/s13098-017-0236-y
   PubMedGoogle Scholar
• Stock S, Drabik A, Büscher G, et al. German diabetes management programs improve quality of care and curb costs. Health Affairs. 2010;29(12):2197–2205. doi:10.1377/hlthaff.2009.0799
   Google Scholar
• Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(6):961–973. doi:10.1053/j.ajkd.2008.11.034
   PubMed Web of Science ®Google Scholar
• Odutayo A, Wong CX, Farkouh M, et al. AKI and Long-term risk for cardiovascular events and mortality. J Am Soc Nephrol. 2017;28(1):1.
   PubMedGoogle Scholar
• Costa D, Patella G, Provenzano M, et al. Hyperkalemia in CKD: an overview of available therapeutic strategies. Front Med. 2023:10. doi:10.3389/fmed.2023.1178140
   Google Scholar
• Albakr RB, Sridhar VS, Cherney DZI. Novel therapies in diabetic kidney disease and risk of hyperkalemia: a review of the evidence from clinical trials. Am J Kidney Dis. 2023;82(6):737–742. doi:10.1053/j.ajkd.2023.04.015
   PubMedGoogle Scholar
• Goia-Nishide K, Coregliano-Ring L, Rangel ÉB. Hyperkalemia in diabetes mellitus setting. Diseases. 2022;10(2):20. doi:10.3390/diseases10020020
   PubMedGoogle Scholar
• Sousa AG, Cabral JV, El-Feghaly WB, de Sousa LS, Nunes AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes. 2016;7(5):101–111. doi:10.4239/wjd.v7.i5.101
   PubMedGoogle Scholar
• Batlle D, Arruda J. Hyperkalemic forms of renal tubular acidosis: clinical and pathophysiological aspects. Adv Chronic Kidney Dis. 2018;25(4):321–333. doi:10.1053/j.ackd.2018.05.004
   PubMedGoogle Scholar
• Palmer BF, Kelepouris E, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. Adv Ther. 2021;38(2):949–968. doi:10.1007/s12325-020-01587-5
   PubMed Web of Science ®Google Scholar
• Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213–221. doi:10.1159/000479802
   PubMed Web of Science ®Google Scholar
• Kohsaka S, Okami S, Kanda E, Kashihara N, Yajima T. Cardiovascular and renal outcomes associated with hyperkalemia in chronic kidney disease: a hospital-based cohort study. Mayo Clin Proc. 2021;5(2):274–285. doi:10.1016/j.mayocpiqo.2020.10.001
   Google Scholar
• Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schöttker B. Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Cardiovasc Drugs Ther. 2018;32(2):197–212. doi:10.1007/s10557-018-6783-0
   PubMed Web of Science ®Google Scholar
• Wang X, Kattan MW. Cohort studies. Chest. 2020;158(1):S72–S78. doi:10.1016/j.chest.2020.03.014
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Bothe T, Fietz A-K, Schaeffner E, et al. Diagnostic validity of chronic kidney disease in health claims data over time: results from a cohort of community-dwelling older adults in Germany. Clin Epidemiol. 2024;16:143–154. doi:10.2147/clep.s438096
   PubMedGoogle Scholar